Curcumin
Also sold as: Turmeric extract · Curcuminoids · Curcuma longa
Turmeric-derived curcuminoids studied mainly for knee osteoarthritis symptoms and metabolic biomarkers. Formulation changes absorption and risk, so whole turmeric, concentrated extract and phospholipid complexes are not interchangeable.
Focus Longevity
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Focus: Meta-analyses show small inconsistent signals in selected cognitive domains; this is not established acute focus enhancement.
- Longevity: Cognitive or metabolic marker changes do not establish longer life or Alzheimer prevention; human longevity benefit remains unestablished.
REALITY CHECK // High absorption is not a guarantee of greater benefit or safety. Curcumin has short-term knee-symptom evidence, but it is not a cancer treatment and changes in inflammatory markers do not prove anxiety relief. Rare liver injury remains relevant even though fatty-liver trials report improved enzymes.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No formal NIH UL is established in the dossier. A cited food-additive ADI of 3 mg/kg/day is not a supplement UL and was not live-verified; 2,000 mg/day is a trial dose, not an NIH limit. Both numerical UL fields are therefore null.
Summary
Knee-OA reviews show a consistent short-term symptom signal but low-to-moderate certainty. Metabolic, depression and ulcerative-colitis findings are adjunctive and heterogeneous. Better liver markers in fatty-liver studies coexist with rare idiosyncratic supplement-associated liver injury.
Mechanism
Curcuminoids influence inflammatory and redox signaling in experimental systems, including Nrf2-related pathways. In vitro assay interference limits mechanistic interpretation. Poor solubility and rapid metabolism make oral exposure formulation-dependent.
Typical studied dose
The dossier reports typical trials at 500–2,000 mg curcuminoids/day, often 4–12 weeks for knee symptoms or 6–12 weeks for depression adjuncts. This active-curcuminoid range is not a verified full-product range for a 95% extract, a roughly 20% phytosome or a micellar blend; product-specific calculator thresholds are withheld.
Upper limit
No formal NIH UL is established in the dossier. A cited food-additive ADI of 3 mg/kg/day is not a supplement UL and was not live-verified; 2,000 mg/day is a trial dose, not an NIH limit. Both numerical UL fields are therefore null.
Popular stacks with Curcumin
Not enough stack data yet. A combination with Curcumin appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Whole turmeric rhizome powder Best for: Food exposure rather than concentrated extract equivalence. |
Unstandardized: active content unknown | no comparable trial range | Low and variable systemic exposure. Generally tolerated in culinary amounts. |
Caution [FORM // CHECK_LABEL] Around 2–5% curcuminoids is a dossier estimate; 5% is a label example, not a guaranteed value. No raw-material-to-trial target is assigned. |
| Extract labelled 95% curcuminoids Best for: Checking actual labelled curcuminoid concentration. |
Unstandardized: active content unknown | no comparable trial range | Unmodified extract has poor solubility and rapid metabolism. Higher amounts can cause gastrointestinal symptoms. |
Good option [FORM // CHECK_LABEL] 95% is composition, not absorption. Source trial doses are on a curcuminoid basis rather than a verified full-extract interval, so calculator targets remain unavailable. |
| 95% curcuminoid extract plus separately declared piperine Best for: Comparing a declared extract component and separate piperine amount. |
Unstandardized: active content unknown | no comparable trial range | Piperine can increase exposure by altering metabolism. Gastrointestinal effects and drug interactions need attention. |
Caution [FORM // CHECK_LABEL] The dossier mentions approximately 5–20 mg piperine in products; this is not a universal safe or effective recipe. Do not enter total blend mass as curcuminoid extract. |
| Phospholipid curcumin complex, roughly 18–20% curcuminoids Best for: Product-specific evidence where piperine is undesirable. |
Unstandardized: active content unknown | no comparable trial range | Carrier improves exposure without requiring piperine. Generally tolerated in studied conditions. |
Good option [FORM // CHECK_LABEL] 20% is a marker-composition example; most mass is carrier. No 95%-extract-to-phytosome clinical equivalence is established. |
| Micellar or nanoparticle formulation Best for: Checking exact formulation and trial matching. |
Unstandardized: active content unknown | no comparable trial range | Potentially high exposure; formulation-specific, not a universal superiority claim. Depends on product and exposure. |
Caution [FORM // CHECK_LABEL] Marker fraction is not supplied. No generic milligram conversion or therapeutic target. |
Common label traps
- TRAP_01 // Turmeric 20,000 mg equals 20,000 mg curcuminoids
The front panel may show a raw-material equivalent. Read actual extract weight and curcuminoid fraction; no ratio is assumed here. - TRAP_02 // Curcumin cures cancer
Supportive-care mucositis or radiation-injury trials do not establish anticancer monotherapy efficacy. - TRAP_03 // Piperine always gives exactly 2,000% or 200-fold absorption
Exposure depends on the comparator, formulation and study conditions; these claims are not interchangeable or general dose multipliers. - TRAP_04 // Natural means liver-safe
Rare supplement-associated liver injury can occur, particularly relevant with enhanced-exposure products. Improved enzymes in NAFLD do not negate this risk.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- KNEE OSTEOARTHRITIS Moderate · benefit
Meta-analyses suggest lower pain and stiffness over 4–12 weeks; some comparisons approach NSAID symptom effects, but low-to-moderate certainty, small trials and variable products limit magnitude claims.
PMID 38576215 PMID 38036015 PMID 33511486 - INFLAMMATORY BIOMARKERS Moderate · benefit
RCT syntheses report lower CRP, IL-6 or TNF-alpha, especially with raised baseline inflammation. Publication-bias concerns and surrogate outcomes preclude general disease or anxiety claims.
PMID 36804260 PMID 31121255 PMID 23922235 - LIPID PROFILE Moderate · benefit
Reviews suggest lower triglycerides, total cholesterol and LDL in metabolic-risk groups; HDL results are less consistent. No event-prevention conclusion follows.
PMID 37230418 PMID 40044446 PMID 36264280 - FATTY-LIVER MARKERS Moderate · benefit
ALT/AST and metabolic markers may improve in NAFLD trials; this is not proof of preventing liver outcomes and does not exclude idiosyncratic hepatotoxicity.
PMID 38232906 PMID 37918958 PMID 30653773 - TYPE 2 DIABETES MARKERS Moderate · benefit
Meta-analyses suggest improved fasting glucose, HbA1c or HOMA-IR, with heterogeneous trials. Adjunctive biomarker changes do not replace diabetes care.
PMID 33514002 PMID 41319069 PMID 34331688 - DEPRESSION ADJUNCT Limited · benefit
Small 6–12-week trials suggest symptom-score improvements; heterogeneity and bias may inflate effects. Not a substitute for depression treatment.
PMID 31423805 PMID 28236605 PMID 26610378 - ULCERATIVE COLITIS ADJUNCT Limited · benefit
Small trials suggest increased remission when added to standard treatment such as mesalazine. This is not evidence for monotherapy.
PMID 30424514 PMID 32751776 - RA / SLE Limited · benefit
Small heterogeneous adjunct studies suggest inflammatory-marker or symptom signals; clinical certainty is limited.
PMID 41372521 PMID 34331695 - EXERCISE RECOVERY Limited · benefit
Some muscle-damage or functional-strength measures improve inconsistently; no established long-term strength or endurance gain.
PMID 37408367 - COGNITIVE DOMAINS Limited · benefit
Small inconsistent changes vary by population and formulation; not established Alzheimer prevention or general focus enhancement.
PMID 40579315 PMID 30575152 - ONCOLOGY SUPPORTIVE CARE Limited · benefit
Some reviews suggest reduced oral mucositis or treatment-related injury under oncology supervision. Oral submucous fibrosis is a separate condition, not proof of cancer treatment.
PMID 32515617 PMID 42050478 PMID 34121673 - ANTICANCER MONOTHERAPY No established evidence
No clinical efficacy is established. Positive cellular assays or supportive-care outcomes do not demonstrate tumor control; this is an unestablished claim, not a negative RCT. - LIVER-INJURY SIGNAL Limited · makes it worse
A safety review describes rare supplement-associated hepatotoxicity; incidence and individual susceptibility remain uncertain.
PMID 42364655
Reader questions
How much curcumin is actually in my product?
Check full extract mass, curcuminoid percentage and carrier. A 500 mg product labelled 95% contains a different marker amount from a 500 mg complex labelled 20%; neither establishes equivalent clinical exposure.
Do I need black pepper?
No. Phospholipid and other delivery systems may improve exposure without piperine. Piperine can also affect drug metabolism, so it is not automatically preferable.
Can it damage my liver?
Rare cases associated with supplements are reviewed in the dossier. Stop with yellow skin or eyes, dark urine or unexplained marked itching and seek assessment.
Is this an immediate painkiller?
The strongest knee evidence concerns repeated use over weeks, not a proven on-demand rescue effect.
Can it cause iron deficiency?
The dossier raises iron-chelation and absorption concerns but supplies no dedicated clinical interaction citation. Existing anemia or long-term high exposure warrants clinician review.
Stack interactions
- Caution Anticoagulants / antiplatelets / levothyroxine [CAUTION // REVIEW_CONTEXT]
The small formulation-specific interaction study did not find significant changes under tested conditions. It does not rule out risk with other products, higher exposure or piperine combinations.
PMID 30070343 - Caution Diabetes medicines [CAUTION // REVIEW_CONTEXT]
Possible additive glucose lowering; monitor clinically rather than changing diabetes treatment based on biomarker trials.
PMID 33514002 - Caution Piperine and narrow-therapeutic-index medicines [CAUTION // REVIEW_CONTEXT]
Metabolism and transporter effects could change drug exposure; clinical magnitude is not established for every drug. A pharmacist should review the full product.
PMID 31267856 - Caution Iron supplements / iron deficiency [CAUTION // REVIEW_CONTEXT]
Chelation and impaired absorption are precautionary concerns in the dossier; a dedicated verified clinical interaction paper is not supplied. Review long-term high-dose use with iron deficiency.
Red flags: interactions and who should avoid it
Interactions
Potential additive glucose lowering matters with diabetes medicines. Anticoagulant effects are theoretical; a small Meriva interaction study found no important changes under its tested conditions, not universal safety. Piperine may alter drug metabolism or transport. Iron chelation is a precaution with uncertain clinical magnitude.
Avoid or ask a doctor first if
Avoid with biliary obstruction; gallstones, active liver disease, prior drug-induced liver injury and iron deficiency require clinical review. Avoid medicinal-dose use in pregnancy; lactation data are insufficient. Review perioperative use with the surgical team. Stop and seek assessment for jaundice, dark urine or marked itching; nausea, diarrhea and bloating can occur.
Sources (PubMed, 32)
- The efficacy of curcumin in relieving osteoarthritis: A meta-analysis of meta-analyses.
PMID 38576215 · 2024 · systematic review and meta-analysisMeta-analysis of meta-analyses on OA symptom relief.
- Efficacy and safety of curcumin therapy for knee osteoarthritis: A Bayesian network meta-analysis.
PMID 38036015 · 2024 · systematic review and meta-analysisNetwork meta-analysis of knee-OA curcumin therapy.
- Efficacy and Safety of Turmeric Extracts for the Treatment of Knee Osteoarthritis: a Systematic Review and Meta-analysis of Randomised Controlled Trials.
PMID 33511486 · 2021 · systematic review and meta-analysisKnee-OA RCT synthesis emphasizing product and evidence heterogeneity.
- Antioxidant and anti-inflammatory effects of curcumin/turmeric supplementation in adults: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.
PMID 36804260 · 2023 · systematic review and meta-analysisGRADE inflammatory-marker synthesis.
- Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials.
PMID 31121255 · 2019 · systematic review and meta-analysisInflammatory-disease biomarker synthesis.
- Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis.
PMID 23922235 · 2014 · systematic review and meta-analysisEarlier CRP meta-analysis with bias concerns.
- Effects of curcumin/turmeric supplementation on lipid profile: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.
PMID 37230418 · 2023 · systematic review and meta-analysisGRADE dose-response lipid review.
- An Umbrella Review of Systematic Reviews and Meta-analyses of Randomized Controlled Trials Investigating the Effect of Curcumin Supplementation on Lipid Profiles.
PMID 40044446 · 2025 · systematic review and meta-analysisUmbrella review of lipid outcomes.
- Curcumin and blood lipid levels: an updated systematic review and meta-analysis of randomised clinical trials.
PMID 36264280 · 2022 · systematic review and meta-analysisUpdated lipid RCT synthesis.
- Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.
PMID 38232906 · 2024 · systematic review and meta-analysisNAFLD metabolic and inflammatory marker review.
- Effects of curcumin/turmeric supplementation on the liver enzymes, lipid profiles, glycemic index, and anthropometric indices in non-alcoholic fatty liver patients: An umbrella meta-analysis.
PMID 37918958 · 2024 · systematic review and meta-analysisNAFLD umbrella review.
- Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials.
PMID 30653773 · 2019 · systematic review and meta-analysisNAFLD liver-enzyme review.
- Potential Therapeutic Effects of Curcumin on Glycemic and Lipid Profile in Uncomplicated Type 2 Diabetes-A Meta-Analysis of Randomized Controlled Trial.
PMID 33514002 · 2021 · systematic review and meta-analysisType 2 diabetes glycemic and lipid review.
- Antidiabetic and Metabolic Effects of Turmeric (Curcuma Longa) in Patients with Type 2 Diabetes Mellitus or Hyperglycemia - A Systematic Meta-Review and Meta-Analysis.
PMID 41319069 · 2025 · systematic review and meta-analysisDiabetes/hyperglycemia meta-review.
- Effect of Curcumin on Glycemic Control in Patients with Type 2 Diabetes: A Systematic Review of Randomized Clinical Trials.
PMID 34331688 · 2021 · systematic review and meta-analysisClinical-trial review of glycemic control.
- Curcumin for depression: a meta-analysis.
PMID 31423805 · 2020 · systematic review and meta-analysisDepression meta-analysis with small heterogeneous trials.
- Clinical Use of Curcumin in Depression: A Meta-Analysis.
PMID 28236605 · 2017 · systematic review and meta-analysisClinical depression RCT synthesis.
- The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials.
PMID 26610378 · 2016 · systematic review and meta-analysisSmall depression-trial meta-analysis.
- Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PMID 30424514 · 2018 · systematic review and meta-analysisAdjunctive clinical-remission review in ulcerative colitis.
- The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.
PMID 32751776 · 2020 · systematic review and meta-analysisComplementary UC trial review.
- Effects of curcumin and Curcuma longa extract on inflammatory biomarkers in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE): a systematic review and meta-analysis of randomized controlled trials.
PMID 41372521 · 2025 · systematic review and meta-analysisRA/SLE inflammatory-biomarker review.
- The Clinical Use of Curcumin for the Treatment of Rheumatoid Arthritis: A Systematic Review of Clinical Trials.
PMID 34331695 · 2021 · systematic review and meta-analysisRheumatoid-arthritis clinical-trial review.
- The effect of curcumin supplementation on functional strength outcomes and markers of exercise-induced muscle damage: A systematic review and meta-analysis.
PMID 37408367 · 2024 · systematic review and meta-analysisExercise damage and functional-strength review.
- Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis.
PMID 40579315 · 2025 · systematic review and meta-analysisCognitive-aging synthesis with uncertain domain-specific effects.
- Curcumin intervention for cognitive function in different types of people: A systematic review and meta-analysis.
PMID 30575152 · 2019 · systematic review and meta-analysisCognitive-function synthesis across populations.
- Prophylactic and Therapeutic Effects of Curcumin on Treatment-Induced Oral Mucositis in Patients with Head and Neck Cancer: A Meta-Analysis of Randomized Controlled Trials.
PMID 32515617 · 2021 · systematic review and meta-analysisTreatment-induced oral-mucositis supportive-care review.
- Effect of curcumin intervention on radiation-induced injury: a GRADE-based systematic review and meta-analysis.
PMID 42050478 · 2026 · systematic review and meta-analysisRadiation-injury supportive-care review.
- Turmeric in the management of oral submucous fibrosis: A systematic review and meta-analysis.
PMID 34121673 · 2021 · systematic review and meta-analysisOral submucous-fibrosis review; separate from tumor treatment.
- Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?
PMID 37008131 · 2023 · narrative reviewFormulation and bioavailability review.
- Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PMID 42364655 · 2026 · narrative reviewReview of rare supplement-associated liver injury.
- Piperine: Old Spice and New Nutraceutical?
PMID 31267856 · 2019 · narrative reviewPiperine pharmacology review informing interaction precautions.
- Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva®).
PMID 30070343 · 2018 · clinical or mechanistic studySmall formulation-specific interaction study with anticoagulants, antiplatelets and thyroid replacement.
Community comments
No approved comments yet. Comments are held for moderation.